Emergent BioSolutions Inc. (EBS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jessica Fye
JPMorgan Chase & Co, Analysis Division

Nice. Welcome, everybody. My identify is Jess Fye. I am a biotech analyst at JPMorgan. And we’re persevering with our forty fourth Annual Healthcare Convention at the moment with Emergent.

First, you are going to hear a presentation from the corporate, after which we’ll have some Q&A. So for these of you within the room, if you wish to ask a query, simply elevate your hand, somebody will convey you a microphone for the webcast. And alternatively, for these listening on-line, you may submit questions through the portal, and I can learn them off the iPad up right here. So with that out of the best way, let me move it over to Emergent’s CEO, Joe Papa.

Joseph Papa
CEO, President & Director

Thanks. Good afternoon, everybody. Welcome to the Emergent presentation. It is my pleasure to speak to these of you right here at the moment within the room and people on the webcast. Emergent is a 25-year-old firm. Our mission is to guard and save lives. We now have — in 2024, began a multiyear turnaround plan. And it is my pleasure at the moment to replace you on our progress of the place we’re with that turnaround plan and simply what we see for the longer term.

So let me go to the — that is simply our secure harbor assertion. So I will be making some feedback at the moment that I will refer you to our SEC filings for any further data and danger components for you.

So what’s the overview of Emergent? Emergent is an organization, as I discussed, 25 years